Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05054530




Registration number
NCT05054530
Ethics application status
Date submitted
12/09/2021
Date registered
23/09/2021
Date last updated
30/01/2024

Titles & IDs
Public title
Assessment of the Safety, Tolerability, and Pharmacokinetic of GMA106
Scientific title
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF GMA106 IN HEALTHY, OVERWEIGHT AND OBESE ADULTS
Secondary ID [1] 0 0
GMA106-I-101
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Overweight and Obesity 0 0
Condition category
Condition code
Diet and Nutrition 0 0 0 0
Obesity

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - GMA106 Injection
Treatment: Drugs - GMA106 Matching Placebo

Experimental: GMA106 - 9 different dosages will be subcutaneously injected into the abdomen.

Placebo Comparator: Matching placebo - 9 different dosages will be subcutaneously injected into the abdomen.


Treatment: Drugs: GMA106 Injection
GMA106 solution for injection. Subjects in each cohort will receive a single injection of GMA106 or matching placebo under fasting conditions and at the following target dose levels.

Treatment: Drugs: GMA106 Matching Placebo
Matching Placebo for GMA106
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Nature, incidence and severity of treatment emergent adverse events
Timepoint [1] 0 0
up to 150±5 days post injection
Primary outcome [2] 0 0
Nature, incidence and severity of treatment emergent adverse events
Timepoint [2] 0 0
up to 227±5 days post first injection
Secondary outcome [1] 0 0
Pharmacokinetic (PK) profile of GMA106 and GMA106 total antibody following single SC administration in healthy subjects.
Timepoint [1] 0 0
Up to 30±1 day for GMA106 and up to 150±5 days post injection for GMA106 total antibody
Secondary outcome [2] 0 0
Pharmacokinetic (PK) profile of GMA106 and GMA106 total antibody following multiple SC administration in overweight or obese subjects.
Timepoint [2] 0 0
Up to 107±3 day for GMA106 and up to 227±5 days post the first injection for GMA106 total antibody
Secondary outcome [3] 0 0
Pharmacokinetic (PK) profile of GMA106 and GMA106 total antibody following single SC administration in healthy subjects.
Timepoint [3] 0 0
Up to 30±1 day for GMA106 and up to 150±5 days post injection for GMA106 total antibody
Secondary outcome [4] 0 0
Pharmacokinetic (PK) profile of GMA106 and GMA106 total antibody following multiple SC administration in overweight or obese subjects.
Timepoint [4] 0 0
Up to 107±3 day for GMA106 and up to 227±5 days post the first injection for GMA106 total antibody
Secondary outcome [5] 0 0
Pharmacokinetic (PK) profile of GMA106 and GMA106 total antibody following single SC administration in healthy subjects.
Timepoint [5] 0 0
Up to 30±1 day for GMA106 and up to 150±5 days post injection for GMA106 total antibody
Secondary outcome [6] 0 0
Pharmacokinetic (PK) profile of GMA106 and GMA106 total antibody following multiple SC administration in overweight or obese subjects.
Timepoint [6] 0 0
Up to 107±3 day for GMA106 and up to 227±5 days post the first injection for GMA106 total antibody

Eligibility
Key inclusion criteria
SAD:

Subjects must meet all of the following criteria:

1. Male or female.

2. = 18 and = 60 years of age.

3. BMI > 20.0 and < 32.0 kg/m2 and body weight = 50.0 kg for males and = 45.0 kg for
females.

4. Non-smoker or light-smoker (=5 cigarettes or equivalent of nicotine per day within 2
months) prior to screening. A Light smoker must agree to abstain from smoking from
screening until after the last PK blood sample collection for GMA106 (Day 30±1), =5
cigarettes or equivalent of nicotine are permitted after that.

5. Healthy conditions are defined as:

1. The absence of currently significant illness and surgeries, within 4 weeks prior
to study drug administration.

2. The absence of disease history, such as diseases of neurological, endocrine,
cardiovascular, respiratory, hematological, immunological, psychiatric,
gastrointestinal, renal, hepatic, and chronic condition of the urogenital,
reproductive, musculoskeletal, endocrine systems, or cancer history.

6. On top of at least one contraceptive method used by his or her partner, male or female
subjects must agree to use at least one contraceptive method throughout the study
period, except total abstinence from heterosexual intercourse (when this is in line
with the preferred and usual lifestyle of the subjects).

1. Female subjects with childbearing potential must agree to use at least one of the
following contraceptive methods throughout the study period:

- On top of condom used by her male partner, in case of a female subject who
likes to use hormonal contraceptives, the hormone must be used 4 weeks prior
to study drug administration.

- On top of condom used by her male partner, in case of a female subject who
likes to use intra-uterine contraceptive device, the device must be placed
at least 4 weeks prior to study drug administration.

- On top of condom used by her male partner, in case of a female subject who
likes to use diaphragm or cervical cap, the method must be started at least
21 days prior to study drug administration.

* Contraceptive requirements for women of non-childbearing potential are
defined as:

- Postmenopausal for 1 year, not taking hormone therapy at screening, and
confirmed by FSH at screening.

- Surgically sterile women mean women who have been surgically sterilized
(defined as hysterectomy, bilateral salpingectomy AND bilateral
oophorectomy). Females who have only had hysterectomy (not including
bilateral salpingectomy and bilateral oophorectomy) or tubal ligation or
other birth control operations are NOT included.

- Only on this premise, surgically sterile women, or post-menopausal women are
the women of non-childbearing potential, and do not need to use
contraception.

2. Male subjects must agree to use at least one of the following contraceptive
methods throughout the study period:

- On top of hormonal contraceptives or intra-uterine contraceptive devices
used by his female partner at least 4 weeks prior to study drug
administration, the male subject must use condoms from study drug
administration.

- On top of diaphragm or cervical cap used by his female partner, the male
subject must use condoms from study drug administration.

3. Male subjects (including men who have had a vasectomy) with a pregnant partner
must agree to use a condom from study drug administration.

7. Male subjects must agree not to donate sperm throughout the study period.

8. Female subjects must agree not to donate ovules throughout the study period.

9. Participants with same-sex partners as well as abstinence from penile-vaginal
intercourse are eligible for the study without needing contraception when this is
their usual form of sexual relations.

10. Capable and agree to give informed consent prior to any study-specific
activities/procedures.

11. Subjects must agree to maintain current general diet and physical activity regimen,
except for the physical activity in the 72 hours before each blood sample collection
for the clinical laboratory analysis, which should not be strenuous.

MAD:

Subjects must meet all of the following criteria:

1. Male or female.

2. = 18 and = 60 years of age.

3. BMI = 25.0 and = 40.0 kg/m2.

4. Non-smoker or light-smoker (=5 cigarettes or equivalent of nicotine per day within 2
months) prior to screening. A Light smoker must agree to abstain from smoking from
screening until checking out from the clinical site on Day 4, =5 cigarettes or
equivalent of nicotine are permitted after that.

5. Subjects who are with diagnosis of T2DM and HbA1c = 8.0% at screening are allowed, but
need:

1. Taking metformin only, with stable dose at least 3 months prior to screening. OR

2. Taking exercise and diet control (self-reported).

6. Subjects with well-controlled comorbidities, such as hypertension, dyslipidemia, fatty
liver, obstructive sleep apnea, hypothyroidism, osteoarthritis, pain disorder, reflux
disease and gout, at the discretion of the investigators, are allowed.

7. Have a stable body weight (< 5 kg self-reported change during the previous 8 weeks)
before screening.

8. On top of at least one contraceptive method used by his or her partner, male or female
subjects must agree to use at least one contraceptive method throughout the study
period, except total abstinence from heterosexual intercourse (when this is in line
with the preferred and usual lifestyle of the subject).

1. Female subjects with childbearing potential must agree to use at least one of the
following contraceptive methods throughout the study period:

- On top of condom used by her male partner, in case of a female subject who
likes to use hormonal contraceptives, the hormone must be used 4 weeks prior
to study drug administration.

- On top of condom used by her male partner, in case of a female subject who
likes to use intra-uterine contraceptive device, the device must be placed
at least 4 weeks prior to study drug administration.

- On top of condom used by her male partner, in case of a female subject who
likes to use diaphragm or cervical cap, the method must be started at least
21 days prior to study drug administration.

* Contraceptive requirements for women of non-childbearing potential are
defined as:

- Postmenopausal for 1 year, not taking hormone therapy at screening, and
confirmed by FSH at screening.

- Surgically sterile women means women who have been surgically sterilised
(defined as hysterectomy, bilateral salpingectomy AND bilateral
oophorectomy). Females who have only had hysterectomy (not including
bilateral salpingectomy and bilateral oophorectomy) or tubal ligation or
other birth control operations are NOT included.

- Only on this premise, surgically sterile women, or post-menopausal women are
the women of non-childbearing potential, and do not need to use
contraception.

2. Male subjects must agree to use at least one of the following contraceptive
methods throughout the study period:

- On top of hormonal contraceptives or intra-uterine contraceptive devices
used by his female partner at least 4 weeks prior to study drug
administration, the male subject must use condoms from study drug
administration.

- On top of diaphragm or cervical cap used by his female partner, the male
subject must use condoms from study drug administration.

3. Male subjects (including men who have had a vasectomy) with a pregnant partner
must agree to use a condom from study drug administration.

9. Male subjects must agree not to donate sperm throughout the study period.

10. Female subjects must agree not to donate ovules throughout the study period.

11. Participants with same-sex partners as well as abstinence from penile-vaginal
intercourse are eligible for the study without needing contraception when this is
their usual form of sexual relations.

12. Capable and agree to give informed consent prior to any study-specific
activities/procedures.

13. Subjects must agree to maintain current general diet and physical activity regimen,
with the exception of the 72 hours preceding each blood sample collection for clinical
laboratory analysis, when physical activity should not be strenuous.
Minimum age
18 Years
Maximum age
60 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
SAD:

Subjects who meet any of the following criteria will be excluded from the study:

1. Any clinically significant (in the opinion of the Investigator) abnormality at
physical examination, abnormal laboratory test results or positive test for HIV,
hepatitis B, or hepatitis C found during medical screening. Abnormal laboratory values
will include: liver function tests (LFTs) > 1.5x ULN

2. Clinically significant (in the opinion of the Investigator) presence of acute illness
(e.g., gastrointestinal illness, gall bladder disease [cholecystectomy is allowed],
chronic pancreatitis, infection such as influenza, upper respiratory tract infection)
upon admission to the study site.

3. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine
neoplasia syndrome type 2 (MEN2).

4. History of renal impairment or renal disease and/or estimated glomerular filtration
rate = 90 mL/min (as calculated by Cockroft and Gault formula).

5. Positive urine drug screen, or alcohol breath test at screening or at admission,
positive urine cotinine test at admission.

6. Positive pregnancy test at screening or at admission.

7. Clinically significant ECG abnormalities or vital sign abnormalities (systolic blood
pressure lower than 90 or over 160 mmHg, diastolic blood pressure lower than 50 or
over 95 mmHg, or heart rate less than 45 or over 100 bpm) at screening.

8. History of type 1 hypersensitivity or severe cutaneous adverse reaction to any
medication, or to any excipient in the formulation, or history of significant atopy.

9. Women who intend to become pregnant or are lactating.

10. History of significant alcohol abuse within 1 year prior to screening or regular use
of alcohol within 6 months prior to the screening visit (average weekly alcohol intake
that exceeds 10 units per week, or are unwilling to stop alcohol consumption for 24
hours prior to study treatment administration until the last PK sample collection of
GMA106 of the study on Day 30±1 (1 unit = 12 oz or 360 mL of beer; 5 oz or 150 mL of
wine; 1.5 oz or 45 mL of distilled spirits).

11. History of significant drug abuse within 1 year prior to screening or use of soft
drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs
(such as cocaine, phencyclidine [PCP], crack, opioid derivatives including heroin, and
amphetamine derivatives) within 1 year prior to screening.

12. Participation in a clinical research study involving the administration of an
investigational or marketed drug or device within 30 days or 5 x T1/2 whichever is
longer prior to dosing, administration of a biological product in the context of a
clinical research study within 90 days or 5 x T1/2 whichever is longer prior to
dosing, or concomitant participation in an investigational study involving no drug or
device administration.

13. Use of medications for the timeframes specified below, with the exception of hormonal
contraception, medications exempted by the Investigator on a case-by- case basis
because they are judged unlikely to affect the pharmacokinetic profile of the study
treatment or subject safety (e.g., topical drug products without significant systemic
absorption):

1. Prescription medications within 14 prior to study treatment administration;

2. Over-the-counter (OTC) products and natural health products (including herbal
remedies homeopathic and traditional medicines, probiotics, food supplements such
as vitamins, minerals, amino acids, essential fatty acids, and protein
supplements used in sports) within 7 days prior to study treatment
administration, with the exception of the occasional use of
paracetamol/acetaminophen (up to 2 g daily) and ibuprofen (up to 800 mg daily);

3. Depot injection or implant of any drug within 3 months prior to study treatment
administration.

14. Live or live attenuated vaccine within 3 months prior to study drug administration and
live or live attenuated vaccine planned over the course of the study.

15. COVID-19 vaccine within 14 days prior to study drug administration and within Day 30±1
after study treatment administration.

16. Have received chronic (>14 consecutive days) systemic glucocorticoid therapy (except
for topical, intra-articular and inhaled preparations) within the last 12 months or
have received any glucocorticoid therapy within 30 days before screening.

17. Receiving treatment or participation in an organized weight loss program that may
cause significant weight gain or loss within 3 months before screening or scheduled
within the study duration period.

18. Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding
volume drawn at screening) of 50 mL to 499 mL of blood within 30 days, or more than
499 mL within 56 days prior to study treatment administration.

19. Any reason which, in the opinion of the Investigator, would prevent the subject from
participating in the study.

MAD:

Subjects who meet any of the following criteria will be excluded from the study:

1. Positive test for HIV, hepatitis B, or hepatitis C found during medical screening.

2. Clinically significant abnormal laboratory test results found during medical
screening. Among which, the exclusion criteria for AST, ALT and/or total bilirubin >2
x ULN, HbA1c > 8%, fasting serum glucose > 144 mg/dL (8.0 mmol/L), and/or a
triglyceride level >500 mg/dL (5.65 mmol/L).

3. Any clinically significant abnormality detected during the physical examination, at
the discretion of the investigators.

4. Clinically significant ECG abnormalities or vital sign abnormalities (systolic blood
pressure lower than 90 or over 160 mmHg, diastolic blood pressure lower than 50 or
over 95 mmHg, or heart rate less than 45 or over 100 bpm) at screening.

5. Currently significant illness and surgeries, within 4 weeks prior to dosing.

6. History of chronic diseases, such as diseases of neurological, respiratory,
hematological, immunological, psychiatric, gastrointestinal, renal, and chronic
conditions of the urogenital, reproductive, musculoskeletal systems, or cancer
history.

7. Had chronic or acute pancreatitis any time prior to study entry.

8. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine
neoplasia syndrome type 2 (MEN2).

9. History of renal impairment or renal disease and/or estimated glomerular filtration
rate = 90 mL/min (as calculated by Cockroft and Gault formula).

10. History of ketoacidosis or hyperosmolar state/coma.

11. Any other types of diabetes except T2DM.

12. Treated with dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon like peptide-1
receptor agonists (GLP-1 RAs), glucose-dependent insulinotropic polypeptide receptor
(GIPR) agonists/antagonists, insulin or any other oral glycemic-lowering agents except
metformin, within 3 months before screening.

13. Positive urine drug screen or alcohol breath test at screening or at admission;
positive urine cotinine test at admission.

14. Positive pregnancy test at screening or at admission.

15. History of type 1 hypersensitivity or severe cutaneous adverse reaction to any
medication, or to any excipient in the formulation; history of significant atopy.

16. Women who intend to become pregnant or are lactating.

17. History of significant alcohol abuse within 1 year prior to screening or regular use
of alcohol within 6 months prior to screening (average weekly alcohol intake that
exceeds 10 units per week); do not agree to stop alcohol consumption from 24 hours
prior to study drug administration until the last PK sample collection of GMA106 of
the study on Day 107±3. (1 unit = 12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5
oz or 45 mL of distilled spirits).

18. History of significant drug abuse within 1 year prior to screening; use soft drugs
(such as marijuana) within 3 months prior to screening; use hard drugs (such as
cocaine, PCP, crack, opioid derivatives including heroin, and amphetamine derivatives)
within 1 year prior to screening.

19. Participation in a clinical research study involving an investigational or marketed
drug or device within 30 days or 5 x T1/2 (whichever is longer) prior to dosing;
administration of a biological product in the context of a clinical research study
within 90 days or 5 x T1/2 (whichever is longer) prior to dosing; concomitant
participation in an investigational study involving no drug or device administration.

20. Timeframes for using medications (including over-the-counter [OTC] or prescription
medicines) are specified below, with the exception of hormonal contraception,
medications that are used to treat overweight/obese comorbidities (eg metformin,
antihypertensives, lipid-lowering treatments, thyroid medications, pain medications,
anti-gout drug etc.), and medications exempted that unlikely to affect the PK profile
of the investigational drug or the safety of the subject as determined by the
Investigator on a case-by-case basis (e.g., topical drug products without significant
systemic absorption):

1. Prescription medications within 14 days prior to study drug administration.

2. OTC products (except products for pain) and natural health products (including
herbal remedies homeopathic and traditional medicines, probiotics, food
supplements such as vitamins, minerals, amino acids, essential fatty acids, and
protein supplements used in sports) within 7 days prior to study drug
administration.

3. Depot injection or implant of drug within 3 months prior to study drug
administration.

21. Live or live attenuated vaccine within 3 months prior to study drug administration;
live or live attenuated vaccine planned throughout the study period.

22. COVID-19 vaccine within 14 days prior to study drug administration; COVID-19 vaccine
planned within 30 days after the last dose of study drug administration (Day 107±3),
except permitted by the Investigator on a case-by-case basis to ensure that it is
appropriate for the subject to take the vaccination.

23. Have received chronic (>14 consecutive days) systemic glucocorticoid therapy (except
for topical, intra-articular and inhaled preparations) within the last 12 months or
have received any form of glucocorticoid therapy within 30 days before screening.

24. Receiving weight loss treatment or participating in an organized weight loss program
within 3 months before screening, or schedule the weight loss treatment or program
within the study period.

25. Donate plasma within 7 days prior to study drug administration; donate or lose 50 mL
to 499 mL of blood (excluding volume drawn at screening) within 30 days prior to study
drug administration; donate or lose more than 499 mL of blood (excluding volume drawn
at screening) within 56 days prior to study drug administration.

26. Any reason which, in the opinion of the Investigator, would prevent the subject from
participating in the study.

Study design
Purpose of the study
Basic Science
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
11/11/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
17/11/2023
Sample size
Target
Accrual to date
Final
73
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 0 0
CMAX Clinical Research - Adelaide
Recruitment postcode(s) [1] 0 0
5000 - Adelaide

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Gmax Biopharm Australia Pty Ltd.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This will be a single centre, Phase 1, placebo-control, randomized, double-blind, sequential
single and multiple ascending dose study to assess the safety, tolerability, and PK of GMA106
in healthy, overweight or obese subjects.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05054530
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Sepehr Shakib, Prof
Address 0 0
CMAX Clinical Research
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05054530